Gyre Therapeutics (NASDAQ:GYRE) First Quarter 2025 Results

Key Financial Results

• Revenue: US$22.1m (down 19% from 1Q 2024).

• Net income: US$2.70m (down 64% from 1Q 2024).

• Profit margin: 12% (down from 28% in 1Q 2024). The decrease in margin was driven by lower revenue.

• EPS: US$0.031 (down from US$0.09 in 1Q 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Gyre Therapeutics shares are up 2.9% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 1 warning sign for Gyre Therapeutics you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.